NCT01856478 2026-01-12
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
Boehringer Ingelheim
Eastern Cooperative Oncology Group
Boehringer Ingelheim
National Cancer Institute (NCI)